Coartem (developed by Novartis) is a fixed-dose Artemisinin-based Combination Therapy (ACT) containing two synergistic active antimalarial agents: artemether and lumefantrine.
-
Artemether: A semi-synthetic endoperoxide derivative of artemisinin that undergoes rapid endoperoxide cleavage by free iron inside the parasite. This produces reactive oxygen species (free radicals) that destroy essential parasite proteins and lipids, resulting in rapid reduction of the parasite burden within hours.
-
Lumefantrine: A lipophilic aryl-amino alcohol derivative that acts over an extended duration by inhibiting the polymerization of toxic heme into inert hemozoin within the parasite’s food vacuole. The accumulated toxic heme causes irreversible membrane damage and clears remaining residual parasites, preventing disease recrudescence.
This dual-action approach combines rapid clearance of symptoms and parasitemia with long-acting eradication, delaying the emergence of drug resistance.
Primary Medical Indications
Coartem is indicated for adult and pediatric patients for the treatment of specific protozoal parasitic infections:
-
Uncomplicated Plasmodium falciparum Malaria: First-line treatment for acute, uncomplicated infections caused by P. falciparum or mixed infections including P. falciparum.
-
Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains resistant to chloroquine, sulfadoxine-pyrimethamine, and other legacy antimalarials.
-
Treatment of Non-falciparum Species: Effective against Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, though radical cure for P. vivax and P. ovale hypnozoites requires additional therapy with primaquine or tafenoquine.
Key Product Specifications & Dosing Forms
| Feature | Specification |
| Active Ingredients | Artemether + Lumefantrine |
| Pharmacological Class | Artemisinin-based Combination Therapy (ACT) Antimalarial |
| Available Formulations | Oral conventional tablets, dispersible oral tablets (Coartem Dispersible for children) |
| Common Strengths | 20 mg / 120 mg standard tablets; 80 mg / 480 mg (Coartem Forte) |
| Standard Regimen |
6-dose regimen given over 3 days (68 hours total):
• Dose 1: At time of diagnosis
• Dose 2: 8 hours later
• Doses 3–6: Twice daily (morning & evening) for the next 2 days |
| Administration | Must be taken with high-fat food or milk (e.g., full-cream milk, oil, or a fatty meal) because lumefantrine absorption increases up to 16-fold when co-administered with lipids |
Critical Safety Guidelines & Precautions
-
Must Be Taken with Fatty Food or Milk: Lumefantrine is extremely lipophilic and relies on dietary fat for systemic absorption. Failure to consume food or milk with each dose significantly lowers plasma levels, risking treatment failure and recrudescence.
-
Re-Dosing After Vomiting: If vomiting occurs within 1 hour of administration, a full replacement dose should be taken immediately. If vomiting persists, alternative parenteral therapy (e.g., IV artesunate) is required.
-
QT Prolongation Warning: Lumefantrine can prolong the QTc interval on the electrocardiogram. Avoid co-administration with other QT-prolonging drugs (e.g., quinine, halofantrine, antiarrhythmics, macrolide antibiotics) or in patients with congenital long QT syndrome or severe hypokalemia.
-
Not for Severe/Complicated Malaria: Strictly contraindicated as monotherapy for severe, complicated malaria (e.g., cerebral malaria, severe anemia, acute kidney injury). Patients with severe malaria require immediate intravenous antimalarial treatment.
-
Prophylaxis Restriction: Coartem is strictly a therapeutic curative agent and must not be used for malaria prophylaxis.
Reviews
There are no reviews yet.